US 12,077,591 B2
TrkA antibody and application thereof
Xiaoming Guan, Jiangsu (CN); Chen Lv, Jiangsu (CN); Bai Lu, Jiangsu (CN); Gang Lu, Jiangsu (CN); Jun Zhou, Jiangsu (CN); Dong Yang, Jiangsu (CN); Jie Xie, Jiangsu (CN); and Jing Su, Jiangsu (CN)
Assigned to 4B TECHNOLOGIES (SUZHOU) LIMITED, Suzhou (CN)
Filed by 4B TECHNOLOGIES (SUZHOU) LIMITED, Jiangsu (CN)
Filed on May 25, 2023, as Appl. No. 18/323,438.
Application 18/323,438 is a continuation of application No. PCT/CN2022/142180, filed on Dec. 27, 2022.
Claims priority of application No. PCT/CN2021/142017 (WO), filed on Dec. 28, 2021.
Prior Publication US 2024/0002516 A1, Jan. 4, 2024
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 25/04 (2006.01)
CPC C07K 16/2863 (2013.01) [A61P 25/04 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 14 Claims
 
1. An antibody or an antigen binding fragment thereof, which is capable of specifically binding to TrkA, the antibody or the antigen binding fragment thereof comprises a light chain CDR1, a light chain CDR2, a light chain CDR3, a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3, wherein:
1) the light chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NOs: 28, 30, and 32 respectively, and the heavy chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NOs: 20, 23, and 26 respectively, or
2) the light chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NOs: 88, 30, and 32 respectively, and heavy chain CDR1-3 comprises the amino acid sequence as set forth in SEQ ID NOs: 20, 87, and 26 respectively.